Topical hypericin: a promising photodynamic therapy for early-stage cutaneous T-cell lymphoma

Effective skin-directed therapies (SDT) are the cornerstone for managing early-stage Cutaneous T-cell Lymphoma (CTCL). However, standard treatments like PUVA phototherapy and topical mechlorethamine carry significant drawbacks, including mutagenic risk and treatment-limiting skin reactions. This unmet need has driven demand for safer options. Topical photodynamic therapy with synthetic hypericin (research name: SGX301; trade name: HyBryte™) has emerged as a novel agent addressing this gap.

This review details synthetic hypericin's evolution and its unique non-mutagenic, light-activated mechanism. It generates singlet oxygen, preferentially inducing apoptosis in malignant T-cells. We analyze key clinical trials, including the pivotal Phase III FLASH study, to establish its efficacy and safety in patch- and plaque-stage mycosis fungoides, comparing it to other SDTs.

Topical synthetic hypericin is a significant advancement for early-stage CTCL. Its excellent safety profile, proven efficacy, and non-mutagenic mechanism position it as a valuable first-line option. Minimal local adverse events and limited systemic absorption offer a key long-term safety advantage over conventional phototherapies. Its effectiveness in both patch and plaque lesions makes it a versatile tool, improving outcomes and quality of life for patients.